Improvements in Health-Related Quality of Life in Patients with Psoriatic Arthritis and Moderate-to-Severe Psoriasis Receiving Secukinumab: A Retrospective Study
- Author:
Yong Jun HONG
1
;
Gang Min GO
;
Miri KIM
Author Information
1. Department of Dermatology, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- Publication Type:Original Article
- From:Korean Journal of Dermatology
2022;60(4):220-227
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Psoriasis is a relapsing inflammatory skin disorder that can affect the nails and joints. Psoriatic arthritis (PsA) occurs in up to 30% of patients with psoriasis, leading to chronic articular pain, and impairing quality of life. Secukinumab is a human monoclonal antibody targeting interleukin-17A that has been shown to effectively improve the clinical signs and symptoms of PsA.
Objective:To evaluate the effect of secukinumab on health-related quality of life (HRQOL) in Korean PsA patients.
Methods:We retrospectively investigated the medical records and psoriasis area and severity index (PASI) scores of 13 patients with PsA who completed the psoriatic arthritis impact of disease 12-item questionnaire (PsAID-12) before and 3 months after receiving secukinumab treatment between October 2019 and August 2021 in Yeouido St.Mary’s Hospital.
Results:At week 12, significant reductions in the total and each item PsAID-12 and mean PASI score were observed (p＜0.01). The mean decrease of total PsAID-12 score was 4.8 (95% confidence interval [CI], 3.74∼5.86), with the greatest improvement observed in the item of ‘embarrassment’ (7.15; 95% CI, 5.59∼8.72). Of the 13 patients, 11 (84.6%) and 5 (38.5%) achieved PASI75 and PASI90 response, respectively.
Conclusion:This study showed that secukinumab improves the HRQOL of patients with PsA, implying a positive influence of secukinumab on patients’ physical and mental status in a real-world clinical setting.
